Abstract PD-1 is a key negative regulator of CD8+ T cell activation and is highly expressed by exhausted T cells in cancer and chronic viral infection. Although PD-1 blockade can improve viral and tumor control, physiological PD-1 expression prevents immunopathology and improves memory formation. The mechanisms driving high PD-1 expression in exhaustion are not well understood and could be critical to disentangling its beneficial and detrimental effects.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by C. Nolan
Homewrecker - barbar
There is a spy in your house of love. A stain on your sheets. Snarled in your hair, tattooed on your arms and legs. A scent, trapped in your senses. A sound so quiet, you turn your head to listen. It hesitates before hanging up. Parked in front of your house, across the street, at the corner. In a trenchcoat and sunglasses; an uncommonly common disguise. It’s the lump in your throat that won't be swallowed, subtle tremor in your hands, voice. Every suspicious look you've ever given, received.
“Charles Bonnet and Limerence Walk into a Bar” — barbar
“Look at all these men,” he said. “You’ll never find a more attractive group of men in one place.” He wasn’t one of the ‘attractive men.’ He knew it. I was the oldest woman at the bar. Did he gravitate to me thinking I’d be grateful for the attention? He sat down next to me a little too hard. The cushion wheezed under his weight. His shoulders softened. I was embarrassed for him, but I also felt a small sense of shame about why I was there. I didn’t want to talk about it.
Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Background: PCNSL is an aggressive primary brain tumor. Outcome and treatment options are poor for recurrent/refractory (r/r) disease. Response rates (ORR) range between 30-60% with a progression free survival (PFS) of 2-5 months. Ibrutinib has shown promising clinical response in some B-cell malignancies. This trial investigates Ibrutinib in patients with r/r PCNSL and SCNSL. Methods: Eligible patients had r/r PCNSL or SCNSL, age ? 18, ECOG ?
Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Phase II study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL) Background: PCNSL is an aggressive primary brain tumor. Outcome and treatment options are poor for patients with recurrent/refractory disease. Response rates range between 30-60% with a progression free survival (PFS) of 2-6 months. PI3K inhibition, particular of the delta isoform, has shown promising clinical response in some B-cell malignancies.
Longitudinal change in ultrasound measurement of rectus femoris cross-sectional area in COPD
Longitudinal change in ultrasound measurement of rectus femoris cross-sectional area in COPD Alex Labey, J.L. Canavan, C.M. Nolan, S.E. Jones, S.S.C. Kon, M.I. Polkey, M. Maddocks, W.D.C. Man European Respiratory Journal Sep 2016, 48 (suppl 60) PA1566; DOI: 10.1183/13993003.congress-2016.PA1566
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with C.
Contact C., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack